Japanese society of dialysis therapy treatment guidelines for secondary hyperparathyroidism

被引:34
作者
Kazama, Junichiro James [1 ]
机构
[1] Niigata Univ, Med & Dent Hosp, Div Intens Care Med, Niigata 9518510, Japan
关键词
life prognosis; parathyroid function; parathyroid intervention; secondary hyperparathyroidism; vitamin d therapy;
D O I
10.1111/j.1744-9987.2007.00516.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Impairment of renal function causes various abnormalities of bone mineral metabolism including secondary hyperparathyroidism. The Japanese Society of Dialysis Therapy proposed the guidelines for the treatment of secondary hyperparathyroidism in chronic dialysis patients (JSDT guidelines) in 2006. From the perspective of better survival rate, the control goal value was determined to be 3.5-6 mg/dl for phosphorus, 8.4-10.0 mg/dl for calcium, and 60-180 pg/ml for intact PTH levels. When the 3 items cannot be controlled by treatment with an active vitamin D preparation, treatment is considered to be a failure, and intervention treatment of the parathyroid gland is recommended. The adequacy of the JSDT guideline must be evaluated by its clinical application.
引用
收藏
页码:S44 / S47
页数:4
相关论文
共 8 条
[1]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[2]   Role of parathyroid intervention in the management of secondary hyperparathyroidism [J].
Fukagawa, M ;
Nakanishi, S .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 :23-26
[3]   Skeletal resistance to PTH as a basic abnormality underlying uremic bone diseases [J].
Fukagawa, M ;
Kazama, JJ ;
Shigematsu, T .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) :S152-S155
[4]   Definition, evaluation, and classification of renal osteodystrophy:: A position statement from kidney disease:: Improving global outcomes (KDIGO) [J].
Moe, S. ;
Drueke, T. ;
Cunningham, J. ;
Goodman, W. ;
Martin, K. ;
Olgaard, K. ;
Ott, S. ;
Sprague, S. ;
Lameire, N. ;
Eknoyan, G. .
KIDNEY INTERNATIONAL, 2006, 69 (11) :1945-1953
[5]  
NAKAI S, IN PRESS THER APHER
[6]   INTACT PARATHYROID-HORMONE OVERESTIMATES THE PRESENCE AND SEVERITY OF PARATHYROID-MEDIATED OSSEOUS ABNORMALITIES IN UREMIA [J].
QUARLES, LD ;
LOBAUGH, B ;
MURPHY, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (01) :145-150
[7]   Challenges in the therapy of secondary hyperparathyroidism [J].
Wood, C ;
González, EA ;
Martin, KJ .
THERAPEUTIC APHERESIS AND DIALYSIS, 2005, 9 (01) :4-8
[8]  
2003, AM J KIDNEY DIS S3, V42, pS7